To date, somatic BRCA1 mutations were reported in 5–9% of sporadic ovarian cancer cases, whereas somatic genetic variants of BRCA2 were identified in 3–4% of tumors 11, 12, 13, 14, 15. This evidence concerns the gene BRCA1 and ovarian carcinoma.